Develops cancer therapies targeting tumors and immune systems.
Dec 2024Revenue $0.00/yrExpenses $53.6M/yr
No trend
Figures by year
When will Apollomics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $0.00 and expenses $53.6M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $53.6M | −$53.6M |
| Dec 2023 | $0.00 | $173M | −$173M |
| Dec 2022 | $0.00 | $241M | −$241M |
| Dec 2021 | $0.00 | $94.8M | −$94.8M |
| Dec 2020 | $0.00 | $74.9M | −$74.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.